{"text": "Eligible patients with stage III or stage IV cancers would undergo a single course of induction chemotherapy followed by concomitant chemoradiation followed by adjuvant chemotherapy in order to avoid mutilating surgery .", "label": "", "metadata": {}, "score": "22.553406"}
{"text": "Eligible patients had squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma .All patients were stage IVa , IVb , or stage III base or tongue or hypopharyngeal tumors .", "label": "", "metadata": {}, "score": "30.49516"}
{"text": "On average , the patients eligible for inclusion in a clinical trial at the onset of palliative chemotherapy received a slightly higher number of chemotherapy lines and were exposed for a longer time to the different chemotherapeutic drugs ( Table 3 ) .", "label": "", "metadata": {}, "score": "32.696712"}
{"text": "Patients may be eligible to participate in a randomized clinical trial for treatment of dysplasia using topical application of retinoids .Treatment of Advanced Non - Small - Cell Lung Cancer in Special Populations .", "label": "", "metadata": {}, "score": "32.75681"}
{"text": "Patients may not be on any other investigational agents or concurrent chemotherapy , radiotherapy , hormonal treatments , bone marrow transplantation , or immunotherapy .Patients who have previously had a Bone Marrow Transplant are excluded from this study .", "label": "", "metadata": {}, "score": "34.45183"}
{"text": "The eligibility criteria for a treatment strategy with successive chemotherapy lines were not investigated in this retrospective series , but only patients without severe cancer - related symptoms , with low tumor burden and who are eligible for a close follow - up were treated with this strategy .", "label": "", "metadata": {}, "score": "35.057526"}
{"text": "Patients with prior radiotherapy are eligible provided a minimum of 4 weeks have passed and the maximal area of hematopoietic active bone marrow treated was less than 25 % .", "label": "", "metadata": {}, "score": "36.970776"}
{"text": "HIV - positive patients receiving combination anti - retroviral therapy are excluded .Ascites requiring active medical management including paracentesis , peripheral bilateral edema , hyponatremia ( serum sodium value less than 134 Meq / L ) .", "label": "", "metadata": {}, "score": "37.60768"}
{"text": "At initial diagnosis , 16 % of resectable cancers , 17 % of locally advanced cancers , and 26 % of metastatic cancers were determined to have HER-2/neu overexpression .", "label": "", "metadata": {}, "score": "38.42496"}
{"text": "Only 6 % of patients treated with chemotherapy alone received cetuximab after the study was completed .Thus , cetuximab has become a key drug for the treatment of recurrent and/or metastatic HNSCC ; however , its most effective place in the treatment strategy remains to be determined .", "label": "", "metadata": {}, "score": "39.26395"}
{"text": "HER-2/neu - negative patients received the same chemoradiation without trastuzumab as a control for toxicity .Dose - limiting toxicities were defined as grade 3 esophageal , cardiac , or pulmonary toxicity .", "label": "", "metadata": {}, "score": "40.24833"}
{"text": "Disease must be considered potentially curable by chemoradiation .Patients medically unfit for cisplatin chemotherapy due to one or more of the following reasons : .", "label": "", "metadata": {}, "score": "40.47819"}
{"text": "Documented progressive disease after platinum - based systemic chemotherapy ( either cisplatin or carboplatin ) with or without cetuximab .At least one bidimensionally measurable disease .", "label": "", "metadata": {}, "score": "41.29541"}
{"text": "Current and future studies exploring the roles of induction , EGFR , radiosensitization , and maintenance therapy are underway or planned , .Clinical / Scientific Implications The above study is an interesting attempt to reduce the toxicity of definitive therapy for head and neck cancer through the substitution of of a traditional chemotherapeutic agent with a targeted therapy .", "label": "", "metadata": {}, "score": "41.358315"}
{"text": "Patients may not receive other antineoplastic therapies such as chemotherapy or radiation treatments while on study ; patients may not receive other experimental treatments while on study ; patients requiring radiation treatments during protocol - based treatment will be taken off study .", "label": "", "metadata": {}, "score": "41.569557"}
{"text": "Nevertheless , retrospective analyses and more recent prospective trials have suggested that such patients enjoy longer survival and a better quality of life when treated with chemotherapy .", "label": "", "metadata": {}, "score": "42.641388"}
{"text": "Considering the high rate of comorbidities , impaired nutritional status , and impaired functional status of patients with recurrent and/or metastatic HNSCC , they should be treated with less toxic strategies .", "label": "", "metadata": {}, "score": "43.097347"}
{"text": "Both .Ages .18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects [ Show abstract ] [ Hide abstract ] ABSTRACT : Objectives : To assess the effect on progression - free and overall survival from the addition of cetuximab to paclitaxel - based chemoradiation for patients with squamous cell head and neck cancer from Brown University Oncology Group studies .", "label": "", "metadata": {}, "score": "43.17609"}
{"text": "In addition , the OS reached 13.1 months among patients without classical major exclusion criteria for clinical trials .However , there were more severe adverse events in the arm of patients treated with cetuximab .", "label": "", "metadata": {}, "score": "43.365997"}
{"text": "Organ - preserving surgery was allowed .Patients who did not undergo surgery received two cycles of induction chemotherapy with carboplatin / paclitaxel .Gefitinib 250 mg qd was maintained after therapy for 2 years total .", "label": "", "metadata": {}, "score": "43.387844"}
{"text": "The outcomes of patients treated with first - line platinum - based chemotherapy were consistently acceptable .The median OS of patients treated with a combination of cisplatin and taxanes , carboplatin and taxanes , or a platinum - based combination without taxane were 14.2 , 10.5 and 11.2 months , respectively ( Table 5 ) .", "label": "", "metadata": {}, "score": "43.537285"}
{"text": "For the Expansion Cohort A of Arm C , a minimum of 10 patients with HER2-negative metastatic breast cancer who have had no more than 1 prior chemotherapy regimen for metastatic diseases are eligible .", "label": "", "metadata": {}, "score": "43.903862"}
{"text": "The results of this study need to be confirmed by a randomized , controlled trial ; however , it is clear that the future of head and neck cancer therapy will include a combination of chemotherapy , radiation , and targeted therapies .", "label": "", "metadata": {}, "score": "44.76494"}
{"text": "All ethnic groups are eligible for this trial .Inclusion Criteria - Dose Confirmation Phase Same inclusion criteria as in the Dose Escalation phase described above , except Patients must have an ECOG performance of 0 or 1 .", "label": "", "metadata": {}, "score": "44.79374"}
{"text": "Approximately 15 % of 584 eligible patients were 70 years or older .[5 ] Elderly patients had more leukopenia and neuropsychiatric complications , but efficacy results , including response and survival , were not significantly different from those in the younger cohort .", "label": "", "metadata": {}, "score": "45.14707"}
{"text": "Phase II study results are awaited .No preview \u00b7 Article \u00b7 Nov 2010 \u00b7 Cancer Chemotherapy and Pharmacology .[ Show abstract ] [ Hide abstract ] ABSTRACT : To determine the feasibility and toxicity of the addition of cetuximab to paclitaxel , carboplatin , and concurrent radiation for patients with head and neck cancer .", "label": "", "metadata": {}, "score": "45.189785"}
{"text": "No prior chemotherapy in the metastatic / locally advanced , recurrent incurable setting ; patients may have received prior curative - intention chemotherapy including induction chemotherapy , chemotherapy concurrent with radiation and adjuvant chemotherapy .", "label": "", "metadata": {}, "score": "45.680862"}
{"text": "Data about chemotherapy delivery are summarized in Table 3 .Thirteen patients received the cisplatin , docetaxel and cetuximab combination evaluated in the TPEx trial [ 13 ] .", "label": "", "metadata": {}, "score": "45.799667"}
{"text": "Physicians have historically approached the treatment of elderly patients with skepticism , based on assumptions that chemotherapy is too toxic and of marginal benefit .Patients with a PS of 2 have also been excluded from chemotherapy trials due to early data indicating an unacceptable rate of chemotherapy - related death and no documented survival benefit .", "label": "", "metadata": {}, "score": "45.962776"}
{"text": "The tumors were advanced at the time of initial diagnosis , as 13 ( 7 % ) patients had metastases , 122 ( 62 % ) patients had stage IVa or IVb tumors , and 23 ( 12 % ) patients had stage III tumors .", "label": "", "metadata": {}, "score": "45.975395"}
{"text": "Safety .Five patients ( 3 % ) died as a result of adverse events at least possibly related to chemotherapy .Three of this patient died of febrile neutropenia after first line carboplatin and paclitaxel combination .", "label": "", "metadata": {}, "score": "46.22412"}
{"text": "The aim of this study was to evaluate the overall survival obtained with a first line chemotherapy adapted to patients functional status and the administration of all active drugs within successive lines of chemotherapy .", "label": "", "metadata": {}, "score": "46.56537"}
{"text": "Affiliated with .Abstract .Background .The combination platinum , 5-fluorouracil ( 5-FU ) and cetuximab is the standard first - line regimen of recurrent and/or metastatic head and neck squamous cell carcinoma ( HNSCC ) .", "label": "", "metadata": {}, "score": "46.64623"}
{"text": "The long - term outcomes of selective organ preservation in operable , locally advanced head and neck cancers in two sequential chemoradiotherapy ( CRT ) protocols ( HN-53 , HN-67 ) are reported .", "label": "", "metadata": {}, "score": "47.279045"}
{"text": "The higher response rate observed with combination strategy [ 5 ] has been shown to improve the functional status of patients [ 21 ] .Moreover some patients in this series never received cetuximab .", "label": "", "metadata": {}, "score": "47.43627"}
{"text": "The survival outcomes of patients treated in the first - line setting with chemotherapy regimens adapted to their functional status , followed by several subsequent regimens were comparable with published outcomes of patients treated by platinum , 5-FU and cetuximab .", "label": "", "metadata": {}, "score": "47.562103"}
{"text": "Discussion .The results of this study challenge the use of the platinum , 5-FU and cetuximab combination for the first - line treatment of recurrent and/or metastatic HNSCC .", "label": "", "metadata": {}, "score": "47.858513"}
{"text": "Chemotherapy was given to only 26.7 % of stage IIIA patients , and 21.2 % of stage IIIB / IV patients - a much lower frequency than expected for the overall population .", "label": "", "metadata": {}, "score": "47.882786"}
{"text": "[ 16 ] Moreover , independent of a possible impact on survival , chemotherapy leads to a relatively rapid improvement in disease - related symptoms in PS 2 patients .", "label": "", "metadata": {}, "score": "47.908333"}
{"text": "Protocol to evaluate the role of a new MRI contrast agent for liver imaging .Eligible patients are those with liver tumors ( primary or metastatic ) who are going to have surgical hepatic resection or exploration ( wedge resection ) cryotherapy , etc .", "label": "", "metadata": {}, "score": "47.91508"}
{"text": "Several reasonable treatment options are available , and the decision about which one to recommend is usually based on toxicity profiles and patient preferences .Whether elderly patients should be treated with combination chemotherapy rather than single- agent therapy remains debatable .", "label": "", "metadata": {}, "score": "47.9588"}
{"text": "The primary purpose of this study is to determine the highest dose of ON 01910 .Na that can be safely given as an intravenous infusion over 24 hours once a week in a 3-week cycle to patients with advanced solid tumors .", "label": "", "metadata": {}, "score": "48.342674"}
{"text": "A Phase Ib , Open - label , Dose - escalation Study of the Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel , Fluoropyrimidine Plus Oxaliplatin , Paclitaxel , or Enzalutamide in Patients With Advanced Solid Tumors .", "label": "", "metadata": {}, "score": "48.50473"}
{"text": "[ 15 ] These findings were similar to those reported by Hickish and colleagues from the UK , who concluded that patients with poor PS experienced symptom relief from chemotherapy .", "label": "", "metadata": {}, "score": "48.56525"}
{"text": "-181 , 2002 .Proc Am Soc Clin Oncol 22:639 , 2003 .Kelly K , Giarritta S , Hayes S , et al : Should older patients receive combination chemotherapy for advanced stage non - small cell lung cancer ?", "label": "", "metadata": {}, "score": "48.598984"}
{"text": "Inclusion of at least 150 patients was hoped to provide a sufficient precision in the estimation of the median OS ( less than 6 months confidence interval range ) .", "label": "", "metadata": {}, "score": "48.870674"}
{"text": "All expenses for the imaging and interpretation - unless ordered clinically - are covered by the study grant .Randomized , open - label , controlled multicenter Phase III study in patients with metastatic colorectal cancer .", "label": "", "metadata": {}, "score": "48.99279"}
{"text": "Patients will receive weekly intravenous cetuximab ( initial dose 400mg / m2 in the week prior to commencing radiotherapy , then weekly 250mg / m2)for the duration of the radiotherapy .", "label": "", "metadata": {}, "score": "49.03846"}
{"text": "Patients received 4 weeks of induction cetuximab followed by weekly cetuximab , paclitaxel , carboplatin , and concurrent radiation .Thirty - two patients were assessable for chemoradiation toxicities .", "label": "", "metadata": {}, "score": "49.05795"}
{"text": "Thus , platinum , taxanes and cetuximab appear to be drugs of choice for the treatment of recurrent and/or metastatic HNSCC , and could be used either in combination or as successive therapies .", "label": "", "metadata": {}, "score": "49.06079"}
{"text": "CO;2 - 3 PubMed View Article .Molin Y , Fayette J : Current chemotherapies for recurrent / metastatic head and neck cancer .Anticancer Drugs 2010 , 22 ( 7 ) : 621 - 625 .", "label": "", "metadata": {}, "score": "49.288284"}
{"text": "Alternatively , a positive rebiopsy required primary site resection and neck dissection followed by radiotherapy boost as deemed necessary .Pathologic complete responses occurred in 71 % patients who then completed CRT ; the remaining 29 % patients underwent primary site surgery .", "label": "", "metadata": {}, "score": "49.359974"}
{"text": "There were no DLTs in the first cycle of treatment .Dose reductions were required in 10 of 15 patients at the final dose level due to neutropenia , nausea , vomiting , diarrhea , dehydration , and hand / foot syndrome following a median of 3 cycles of treatment .", "label": "", "metadata": {}, "score": "49.54309"}
{"text": "Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as HIV infection , cardiac failure , pulmonary compromise , active infection .", "label": "", "metadata": {}, "score": "49.62197"}
{"text": "2 non - disease related deaths during treatment .6 months post - CTRT , 4 patients required gastrostomy tube feeding and 1 received hyperbaric oxygen therapy for bone exposure .", "label": "", "metadata": {}, "score": "49.82841"}
{"text": "Ramsey SD , Peacock S , Goodman G , et al : Prevalence of older patients with advanced non - small cell lung cancer receiving no treatment : Evidence from the SEER - Medicare database ( abstract 2586 ) .", "label": "", "metadata": {}, "score": "49.8356"}
{"text": "This program is a Phase II multi - center study incorporating local injections of the gene therapy agent , Allovectin-7 .It is an immunotherapeutic approach intended to stimulate an immune response by expressing HLA - b7 antigen within the tumor and potentially restoring some degree of major histocompatibility complex class I tumor antigen presentation .", "label": "", "metadata": {}, "score": "49.860046"}
{"text": "[ 18 ] The 1-year survival rate was 19 % .Based on this subset analysis , the ECOG investigators concluded that patients with advanced NSCLC and a PS of 2 should not be treated with platinum- based combinations - at least not in the doses and schedule utilized in this trial .", "label": "", "metadata": {}, "score": "49.962196"}
{"text": "[ 10 ] Prospective clinical trials and retrospective analyses in the 1980s suggested that patients with advanced NSCLC and compromised PS experienced substantial toxicity and derived no benefit from systemic chemotherapy .", "label": "", "metadata": {}, "score": "50.10573"}
{"text": "The patient receives three vaccinations at two - week intervals .The patient must undergo one pheresis procedure to isolate dendritic cells .This therapy has shown promising results in preliminary studies of patients with melanoma and breast cancer .", "label": "", "metadata": {}, "score": "50.21189"}
{"text": "Twenty - seven patients ( 12 patients with previous chemotherapy exposure and 15 chemotherapy - naive patients ) were examined for toxicity .Dose escalation was halted due to neutropenia and/or Grade 2/3 neuropathy in both arms .", "label": "", "metadata": {}, "score": "50.433243"}
{"text": "Treatment .Treatment was administered according to clinical practice guidelines ( Figure 1 ) .The choice of first - line therapy depended on the date of treatment onset , the patients ' condition and the efficacy or residual toxicity of previous platinum - based chemotherapy when used in treatment for localized disease .", "label": "", "metadata": {}, "score": "50.58927"}
{"text": "Data retrieval and file selection .We retrospectively reviewed the data of all patients with histologically confirmed recurrent and/or metastatic HNSCC and treated by chemotherapy at a single institution between March 2006 and August 2011 .", "label": "", "metadata": {}, "score": "50.799034"}
{"text": "Schiller JH , Harrington D , Belani CP , et al : Comparison of four chemotherapy regimens for advanced non - small cell lung cancer .", "label": "", "metadata": {}, "score": "50.811222"}
{"text": "37/70 patients were stage T1 - 2 ; 21/70 were stage T4 .56/70 patients were stage N2a or higher .96 % treated with Intensity - Modulated Radiation Therapy ( IMRT ) .", "label": "", "metadata": {}, "score": "50.82969"}
{"text": "free survival and overall survival were also not significantly different between arms .Platinum - Based Chemotherapy Three recent trials from US cooperative groups provided important information about elderly patients treated with platinum - based combination chemotherapy ( Table 2 ) .", "label": "", "metadata": {}, "score": "50.85068"}
{"text": "Patients with adenocarcinoma of the esophagus without distant organ metastases were eligible .All patients received cisplatin 25 mg / m2 and paclitaxel 50 mg / m2 weekly for 6 weeks with radiation 50.4 Gy .", "label": "", "metadata": {}, "score": "50.940887"}
{"text": "Availability of tumor tissue for molecular analysis ( archival or rebiopsy tissue ) .Exclusion Criteria : .Nasopharyngeal carcinoma .Eligibility for local therapy ( surgery or radiotherapy ) .", "label": "", "metadata": {}, "score": "51.05808"}
{"text": "Patients with known interstitial lung disease .Concomitant malignancy ( except adequately treated basal cell cancer of skin or cervical cancer in situ ) .Pregnant or breast - feeding women .", "label": "", "metadata": {}, "score": "51.195236"}
{"text": "Therefore , a treatment strategy , including several lines of chemotherapy , should be formally compared with first - line combinations of multiple drugs in randomized controlled trials .", "label": "", "metadata": {}, "score": "51.251236"}
{"text": "A subsequent analysis of prognostic factors indicated no significant interaction between treatment and any of these factors , except a low PS .Specifically in the PS 2 subset , the combination of cisplatin / vinorelbine did not produce any benefit over the other two regimens , and single - agent vinorelbine was suggested as a reasonable treatment approach .", "label": "", "metadata": {}, "score": "51.332523"}
{"text": "[ Designated as safety issue : No ] .Time to local and/or regional failure [ Time Frame : All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment . ]", "label": "", "metadata": {}, "score": "51.34214"}
{"text": "As of Amendment 7 , up to 6 patients with gynecological malignancies will be enrolled at the 2400 mg / m2 dose level to determine the appropriateness of this dose as the Recommended Phase Two Dose ( RPTD ) .", "label": "", "metadata": {}, "score": "51.380703"}
{"text": "More recent trials , conducted in the late 1990s , started to include PS 2 patients again as a subgroup of the overall study population .", "label": "", "metadata": {}, "score": "51.38879"}
{"text": "Summary The notion that elderly patients are too old to tolerate or benefit from chemotherapy has been conclusively defeated .Age alone should not influence the treatment decision - making process in elderly patients with advanced NSCLC .", "label": "", "metadata": {}, "score": "51.40094"}
{"text": "Hitt R , Irigoyen A , Cortes - Funes H , Grau JJ , Garcia - Saenz JA , Cruz - Hernandez JJ : Phase II study of the combination of cetuximab and weekly paclitaxel in the first - line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck .", "label": "", "metadata": {}, "score": "51.462322"}
{"text": "Correlations of the pre - treatment histology and the expression of genes important in regulating apoptosis are an integral part of this program .It is expected that this treatment will ameliorate the devastating effects of surgery on speech , swallowing and quality of life , without any decrease in cure rates .", "label": "", "metadata": {}, "score": "51.49491"}
{"text": "In this series , deaths related to chemotherapy toxicities were uncommon ( 3 % ) despite the high number of chemotherapy lines administered to patients .", "label": "", "metadata": {}, "score": "51.615616"}
{"text": "The investigators suggest a phase II trial of pan - HER inhibitor PF-00299804 in patients with recurrent or metastatic HNSCC previously treated with platinum - based chemotherapy .", "label": "", "metadata": {}, "score": "51.636932"}
{"text": "Patients will be assessed every eight weeks ( or at time of suspected progression ) .The Head and Neck Oncology Program is initiating a new organ preservation protocol for patients with advanced cancers of the oral cavity / oropharynx .", "label": "", "metadata": {}, "score": "51.63958"}
{"text": "[20 ] These agents can be studied alone or in combination with more standard drugs in PS 2 patients .Conclusions The recognition that elderly and PS 2 patients can benefit from chemotherapy is an important contribution to the management of advanced NSCLC .", "label": "", "metadata": {}, "score": "51.646957"}
{"text": "Tumor assessment by RECIST criteria version 1.1 will be followed at the end of first 28-day treatment , then every 48-day treatment until disease progression Response rate to evaluate the efficacy of PF-00299804 in patients with squamous cell carcinoma of head and neck who failed to platinum - containing treatment .", "label": "", "metadata": {}, "score": "51.776127"}
{"text": "Recurrence and survival data were compared with previous Brown University studies utilizing the same paclitaxel - based chemoradiation with and without induction chemotherapy .Results : The progression - free survival and overall survival at 3 years for all 37 patients initiating chemoradiation was 54 % and 57 % , respectively .", "label": "", "metadata": {}, "score": "51.855095"}
{"text": "A major objective pursued by treating oncologists was to give all the active agents to a maximum of patients , explaining the high rate of patients receiving platinum , taxanes , cetuximab , methotrexate and 5-FU at least once .", "label": "", "metadata": {}, "score": "52.05666"}
{"text": "Eastern Cooperative Oncology Group ( ECOG ) performance status of 0 or 1 at screening .Histologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerable , with the following exceptions : .", "label": "", "metadata": {}, "score": "52.162155"}
{"text": "17 % have discontinued gefitinib during maintenance .Author 's Conclusions .Inclusion of gefitinib into concurrent CTRT is feasible and tolerable .16 % grade 3/4 neutropenia .", "label": "", "metadata": {}, "score": "52.21425"}
{"text": "The 7-month median survival in patients with metastatic pancreatic cancer suggests there may be a modest benefit for some patients .Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer .", "label": "", "metadata": {}, "score": "52.31086"}
{"text": "The 7-month median survival in patients with metastatic pancreatic cancer Suggests there may be a modest benefit for some patients .Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer .", "label": "", "metadata": {}, "score": "52.31086"}
{"text": "This combination represents an easily administered , active regimen for patients with metastatic gastric and esophageal cancers .Further evaluation of this regimen is indicated .", "label": "", "metadata": {}, "score": "52.529152"}
{"text": "This combination represents an easily administered , active regimen for patients with metastatic gastric and esophageal cancers .Further evaluation of this regimen is indicated .", "label": "", "metadata": {}, "score": "52.529152"}
{"text": "Hickish TF , Smith IE , O'Brien ME , et al : Clinical benefit from palliative chemotherapy in non - small - cell lung cancer extends to the elderly and those with poor prognostic factors .", "label": "", "metadata": {}, "score": "52.64602"}
{"text": "Grade 3 and grade 4 radiation dermatitis occurred in 44 % and 9 % of patients , respectively .Grade 3 and grade 4 cetuximab associated acneiform rash developed in 6 % and 3 % of patients .", "label": "", "metadata": {}, "score": "52.6738"}
{"text": "More than one systemic chemotherapy .Any major operation or irradiation within 4 weeks of baseline disease assessment .Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug .", "label": "", "metadata": {}, "score": "52.978737"}
{"text": "10.1097/CAD.0b013e328325a9d7 PubMed View Article .Moosmann P , Egli F , Stahel RA , Jost L : Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck .", "label": "", "metadata": {}, "score": "53.129467"}
{"text": "The percentages of the intended total dose delivered of carboplatin , cetuximab , paclitaxel , and radiation were 86 % , 89 % , 89 % , and 96 % , respectively .", "label": "", "metadata": {}, "score": "53.394646"}
{"text": "In conclusion , our results are very encouraging , but subsequent efficient drugs are now strongly needed .Conclusions .The survival outcomes of patients treated in the first - line setting with chemotherapy regimens adapted to their functional status , followed by several subsequent regimens were comparable with published outcomes of patients treated by platinum , 5-FU and cetuximab .", "label": "", "metadata": {}, "score": "53.582626"}
{"text": "With the increased number of innovative and active agents , strategy trials should become more and more important .The administration of successive chemotherapy lines could spare patients from severe toxic effects , but might not be as efficient as combination strategy in controlling symptoms for patients with severe cancer - related symptoms or with rapidly progressive disease .", "label": "", "metadata": {}, "score": "53.679253"}
{"text": "The results of the CALGB subset analysis showed a significant benefit for combination chemotherapy over single - agent therapy in PS 2 patients , with no decrement in quality of life .", "label": "", "metadata": {}, "score": "53.68965"}
{"text": "Of 14 patients who recurred within 3 years , 7 patients recurred locally only , 5 had a systemic recurrence , and 2 recurred both locally and systemically .", "label": "", "metadata": {}, "score": "53.719448"}
{"text": "Patients with disease amenable to sequential biopsies will be requested to undergo two tumor biopsies and two normal skin biopsies , but patients may decline and still be eligible for enrollment during this escalation stage .", "label": "", "metadata": {}, "score": "53.722656"}
{"text": "Adequate hematologic and end organ function .Exclusion Criteria : .Exceptions are kinase inhibitors approved by local regulatory authorities , which may be used within 2 weeks prior to initiation of GDC-0068 , provided that any clinically - relevant drug - related toxicity has completely resolved and prior approval is obtained from the Medical Monitor .", "label": "", "metadata": {}, "score": "53.9153"}
{"text": "Therapy was active but patients must be carefully selected and monitored .Compared with the historical controls , dose dense and intense induction chemotherapy decreased distant failure rate without compromising the locoregional control .", "label": "", "metadata": {}, "score": "54.35386"}
{"text": "Langer CJ , Manola J , Bernardo P , et al : Cisplatin - based therapy for elderly patients with advanced non - small cell lung cancer : Implications of Eastern Cooperative Oncology Group 5592 , a randomized trial .", "label": "", "metadata": {}, "score": "54.364334"}
{"text": "Proc Am Soc Clin Oncol 20:329a , 2001 .Lilenbaum R , Herndon J , List M , et al : Single - agent versus combination chemotherapy in advanced non - small cell lung cancer : a CALGB randomized trial of efficacy , quality of life , and cost - effectiveness ( abstract 2 ) .", "label": "", "metadata": {}, "score": "54.371017"}
{"text": "Therefore , escalation beyond dose level 5 was not attempted .Ten of 25 patients who could be evaluated ( 40 % ) responded and 8 of 14 patients treated at the final dose level responded ( 57 % ) .", "label": "", "metadata": {}, "score": "54.492615"}
{"text": "The successive chemotherapy lines strategy might then be more suited for patients with low cancer - related symptoms , and with low tumor burden .In this series , only 6 % of the patients were treated in first line with the combination of platinum , 5-FU and cetuximab .", "label": "", "metadata": {}, "score": "54.568535"}
{"text": "In our series , platinum - based combination was the favored first line when patients were fit enough , to avoid subsequent platinum - ineligibility related to disease progression .", "label": "", "metadata": {}, "score": "54.610878"}
{"text": "Previous CHF or other cardiac conditions shall not result in exclusion if the treating physician does not see contraindication to these medications ; if contraindication is controversial , cardiac consultation will be obtained prior to the initiation of therapy .", "label": "", "metadata": {}, "score": "54.79206"}
{"text": "Stage III or IV , excluding T1N1 , and metastatic disease ( to be confirmed by a chest CT , and abdominal CT or ultrasound scan if patients with abnormal liver function tests or a bone scan or FDG - PET if patients with bone pain ) .", "label": "", "metadata": {}, "score": "55.081757"}
{"text": "ABSTRACT : The benefits of chemotherapy in non - small - cell lung cancer ( NSCLC ) patients remains , to some extent , restricted to younger patients with a good performance status ( PS ) .", "label": "", "metadata": {}, "score": "55.092667"}
{"text": "Pre - treatment evaluation includes tumor measurements and a CT scan .Follow - up examinations include CT scanning to objectively document tumor regressions .Clinical Services .", "label": "", "metadata": {}, "score": "55.265854"}
{"text": "Patients will receive 5FU / LV using the Mayo Clinic regimen and SU5416 will be administered twice weekly IV at a dose of 145mg / m2 .", "label": "", "metadata": {}, "score": "55.293358"}
{"text": "Methods : Twenty - eight patients were treated over 5 dose levels in a 21-day cycle .Results : There were no DLTs in the first cycle of treatment .", "label": "", "metadata": {}, "score": "55.35505"}
{"text": "Eight of 12 patients with HER-2/neu overexpression by IHC had an increase in the number of HER-2/neu genes , six from amplification of the HER-2/ neu gene and two were hypderdiploid for chromosome 17 .", "label": "", "metadata": {}, "score": "55.67476"}
{"text": "HER-2/neu overexpression occurs in a subset of pancreatic cancer .Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated .", "label": "", "metadata": {}, "score": "55.751556"}
{"text": "No increase in toxicity was seen with the addition of trastuzumab .Mean left ventricular ejection fraction for the trastuzumab group was 57 % before treatment and 56 % after treatment .", "label": "", "metadata": {}, "score": "55.88069"}
{"text": "One patient died of an aspiration pneumonia on feeding tube a few days after the onset of cisplatin , 5-FU and docetaxel combination .", "label": "", "metadata": {}, "score": "55.88462"}
{"text": "J Natl Cancer Inst 65:25 - 32 , 1980 .Ruckdeschel J , Finkelstein D , Ettinger D , et al : A randomized trial of the four most active regimens for metastatic non - small cell lung cancer .", "label": "", "metadata": {}, "score": "55.92978"}
{"text": "Less than 3 weeks elapsed since prior exposure to chemotherapy .Uncontrolled intercurrent illness including , but not limited to , ongoing or active infection requiring IV antibiotics , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , or psychiatric illness / social situations that would limit compliance with study requirements .", "label": "", "metadata": {}, "score": "55.973717"}
{"text": "Overall long - term failure rates were : 6 % local , 6 % regional , and 32 % distant .This strategy of selective organ preservation was effective in 71 % patients with CRT , whereas salvage surgery was required in the remainder .", "label": "", "metadata": {}, "score": "56.028015"}
{"text": "Exclusion .Patients who have received prior capecitabine chemotherapy or lapatinib .Patients with brain metastases may participate if they have undergone appropriate treatment for the lesion(s ) , are at least two weeks post treatment without evidence for post - treatment progression , have no significant neurologic symptoms , and are no longer on steroids for brain metastases .", "label": "", "metadata": {}, "score": "56.17048"}
{"text": "Analysis .OS was defined as the time elapsed from the first dose of chemotherapy administered for the recurrent and/or metastatic disease .If death did not occur before the cut - off date , the patient was censored at the date of last valid assessment .", "label": "", "metadata": {}, "score": "56.213356"}
{"text": "It is a reasonable treatment option for patients with impaired functional status or severe organ failure to avoid the high toxicity of combination strategy .Declarations .", "label": "", "metadata": {}, "score": "56.319992"}
{"text": "Temel JS , Greer JA , Muzikansky A , Gallagher ER , Admane S , Jackson VA , Dahlin CM , Blinderman CD , Jacobsen J , Pirl WF , Billings JA , Lynch TJ : Early palliative care for patients with metastatic non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "56.401604"}
{"text": "Indeed , taxanes alone [ 9 , 10 ] or taxanes in combination with cetuximab [ 7 , 8 ] , capecitabine [ 11 , 12 ] or methotrexate [ 1 ] are available as subsequent treatment lines .", "label": "", "metadata": {}, "score": "56.628067"}
{"text": "The overall response rate with induction was 79 % .Patients undergoing biopsy of the primary tumor site after the therapies had 17/18 ( 94 % ) pathologic complete response rate .", "label": "", "metadata": {}, "score": "56.656414"}
{"text": "Patients with highly impaired performans status ( Karnofsky score below 50 ) or with highly impaired nutritional status could be ineligible to carboplatin .Carboplatin - ineligible patients and patients treated in the second - line setting who developed a resistance to platinum ( progressive disease less than 6 months after the beginning of platinum ) received a combination of paclitaxel \u00b1 cetuximab .", "label": "", "metadata": {}, "score": "56.72396"}
{"text": "The level of clinical suspicion may be influenced by clinical stage , e.g. , N3 disease , low neck nodes .In general if there is any doubt patients should be excluded .", "label": "", "metadata": {}, "score": "56.78206"}
{"text": "History of clinically significant ventricular arrhythmias or active ventricular arrhythmia requiring medication .For Arm D only : History of seizure , unexplained loss of consciousness , transient ischemic attack within 12 months of enrollment , cerebral vascular accident , and any brain metastases .", "label": "", "metadata": {}, "score": "57.02723"}
{"text": "70 patients consented for the trial , but 1 withdrew consent prior to initiation of any therapy .Median age was 59 ; 70 % were male ; 70 % had ECOG PS of 0 , 24 % were never smokers , and 16 % had organ - preserving surgery prior to CTRT .", "label": "", "metadata": {}, "score": "57.04621"}
{"text": "MTD was defined as the highest dose level at which less than 50 % of patients developed unacceptable toxicity and received more than 80 % of the intended dose during the first cycle .", "label": "", "metadata": {}, "score": "57.152153"}
{"text": "No disability with absorption of internal medications .Adequate nutritional status : Patients will not be excluded based on previous weight loss but will be required to have adequate nutrition at the time of study entry as measured by serum albumin .", "label": "", "metadata": {}, "score": "57.16279"}
{"text": "Severe mucositis occurred in 37 ( 90 % ) patients , necessitating hospitalization in 13 ( 31 % ) patients .With a median follow - up of 49 months , the locoregional and distant failure rates were 26 % and 21 % , respectively .", "label": "", "metadata": {}, "score": "57.218494"}
{"text": "ECOG Subset Analysis -In the United States , ECOG investigators reported a subset analysis of PS 2 patients from trial 1594 , which randomized over 1,200 patients to four platinum - based regimens .", "label": "", "metadata": {}, "score": "57.561543"}
{"text": "Vansteenkiste J , Vandebroek J , Nackaerts K , et al : Influence of cisplatin - use , age , performance status and duration of chemotherapy on symptom control in advanced non - small cell lung cancer : Detailed symptom analysis of a randomised study comparing cisplatin - vindesine to gemcitabine .", "label": "", "metadata": {}, "score": "57.94854"}
{"text": "10.3109/00016480802590451 PubMed View Article .Hitt R , Amador ML , Quintela - Fandino M , Jimeno A , del Val O , Hernando S , Cortes - Funes H : Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck .", "label": "", "metadata": {}, "score": "57.98063"}
{"text": "Gridelli C , Perrone F , Gallo C , et al : Chemotherapy for elderly patients with advanced non - small cell lung cancer : The Multicenter Italian Lung Cancer in the Elderly Study ( MILES ) phase III randomized trial .", "label": "", "metadata": {}, "score": "58.066345"}
{"text": "References .Gridelli C : Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non - small cell lung cancer ?", "label": "", "metadata": {}, "score": "58.08581"}
{"text": "The high number of successive chemotherapy line ( 39 % of patients received 3 lines or more ) might explain patients good outcomes .Because of the heterogeneity of the treatment described in this study , and because of the limitations of a retrospective study , we did not assess the adverse events rates of the successive chemotherapy lines strategy .", "label": "", "metadata": {}, "score": "58.149628"}
{"text": "P\u00e9ron J , Poupart M , Ceruse P , Ramade A , Girodet D , Zrounba P , Fayette J : Efficacy and safety of capecitabine in heavily pretreated recurrent / metastatic head and neck squamous cell carcinoma .", "label": "", "metadata": {}, "score": "58.35499"}
{"text": "Bunn P , Lilenbaum R : Chemotherapy for elderly patients with advanced non - small cell lung cancer .J Natl Cancer Inst 95:341 - 343 , 2003 .", "label": "", "metadata": {}, "score": "58.608177"}
{"text": "The therapy was continued until disease progression or excessive toxicity not amenable to appropriate modifications .Restaging was performed after every 2 cycles .A total of 23 patients were enrolled , with 17 patients evaluable for toxicity assessment .", "label": "", "metadata": {}, "score": "58.6949"}
{"text": "[19 ] A total of 47 and 51 eligible patients , respectively , were treated with attenuated doses of cisplatin / gemcitA total of 47 and 51 eligible patients , respectively , were treated with attenuated doses of cisplatin / gemcitabine and carboplatin / paclitaxel .", "label": "", "metadata": {}, "score": "58.895817"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Novel systemic treatments are needed in pancreatic cancer .The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab ( Herceptin ) as a therapeutic agent in this disease .", "label": "", "metadata": {}, "score": "58.9024"}
{"text": "European Trials -In a phase III study conducted by Le Chevalier and colleagues , the combination of cisplatin and vinorelbine was superior to cisplatin / vindesine and to single - agent vinorelbine .", "label": "", "metadata": {}, "score": "59.052055"}
{"text": "Severe tinnitus .Inability to tolerate intravenous hydration eg due to cardiac disease .Co- morbidities ( based on clinical judgement by the investigator ) associated with ECOG PS 2 that in the view of the investigator would preclude the safe administration of cisplatin .", "label": "", "metadata": {}, "score": "59.098663"}
{"text": "[ 6 ] Again , response rates , survival , and toxicity were comparable in younger and older patients across all the arms .SWOG Trials -Kelly and colleagues performed a similar analysis on behalf of the Southwest Oncology Group ( SWOG ) .", "label": "", "metadata": {}, "score": "59.27475"}
{"text": "Encouraging preliminary results have been obtained in prior studies at a much lower dose of Allovectin-7 .Each treatment in the current protocol will include a series of two injections of 100 micrograms , two weeks apart .", "label": "", "metadata": {}, "score": "59.394463"}
{"text": "Pregnant or lactating women .Weight loss greater than 20 % of usual body weight in the 3 months preceding trial entry .High risk for poor compliance with therapy or follow up as assessed by the investigator .", "label": "", "metadata": {}, "score": "59.478424"}
{"text": "Concurrent paclitaxel , carboplatin , and RT for advanced head and neck cancer results in high complete response rates .Long - term follow - up has revealed the curative potential of this regimen , though the doses used resulted in unacceptable toxicity .", "label": "", "metadata": {}, "score": "59.51861"}
{"text": "Thirty - four patients were enrolled .Thirty patients ( 88 % ) had pancreatic cancers with 2 + overexpression and 4 patients ( 12 % ) had 3 + overexpression .", "label": "", "metadata": {}, "score": "59.532497"}
{"text": "Thirty - four patients were enrolled .Thirty patients ( 88 % ) had pancreatic cancers with 2 + overexpression and 4 patients ( 12 % ) had 3 + overexpression .", "label": "", "metadata": {}, "score": "59.532497"}
{"text": "Integration of Gefitinib into a Concurrent Chemoradiation Regimen Followed by Gefitinib Adjuvant Therapy in Patients with Locally Advanced Head and Neck Cancer :A Phase II Trial .", "label": "", "metadata": {}, "score": "59.809326"}
{"text": "Hussain M , Gadgeel S , Kucuk O , Du W , Salwen W , Ensley J : Paclitaxel , cisplatin , and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck .", "label": "", "metadata": {}, "score": "59.963753"}
{"text": "When used as single agents , FTPase inhibitors and MMPI 's may be cytostatic , helping to delay the growth of these cancers .All three classes of agents may have the greatest benefit when used in conjunction with traditional anticancer modalities .", "label": "", "metadata": {}, "score": "60.019104"}
{"text": "Subsequent lines consisted of inclusion in a clinical trial , methotrexate , or capecitabine , depending on previously given therapies and eligibility in a clinical trial .", "label": "", "metadata": {}, "score": "60.283092"}
{"text": "The median survival of approximately 6 months in both arms was longer than expected based on historical controls ( Table 4 ) .Toxicity followed the expected pattern for these two regimens : Myelosuppression , particularly thrombocytopenia , was more common with cisplatin / gemcitabine , whereas peripheral neuropathy was more frequent with carboplatin / paclitaxel .", "label": "", "metadata": {}, "score": "60.42641"}
{"text": "Patients will receive ON 01910 .Na intravenously by 24 hour continuous infusion once every week ( 3 weeks per cycle ) , until evidence of disease progression , intolerable adverse events , or withdrawal of patient consent .", "label": "", "metadata": {}, "score": "60.663242"}
{"text": "Le Chevalier T , Brisgand D , Douillard JY , et al : Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non - small - cell lung cancer : Results of a European multicenter trial including 612 patients .", "label": "", "metadata": {}, "score": "60.671127"}
{"text": "Tumor assessment by RECIST criteria version 1.1 will be followed every 8 weeks treatment until disease progression .Original Primary Outcome Measures ICMJE ( submitted : October 6 , 2011 ) .", "label": "", "metadata": {}, "score": "60.69203"}
{"text": "Ten of 25 patients who could be evaluated ( 40 % ) responded and 8 of 14 patients treated at the final dose level responded ( 57 % ) .", "label": "", "metadata": {}, "score": "60.911407"}
{"text": "This series included a total of 194 patients with recurrent and/or metastatic HNSCC treated from 2006 to 2011 in a single institution where the administration of successive lines of chemotherapies has been the standard clinical approach .", "label": "", "metadata": {}, "score": "60.921764"}
{"text": "The combination of carboplatin and weekly paclitaxel showed response rates of 48 to 53 % and median survival rates of 8 to 12.8 months in Phase II trials [ 14 , 15 ] .", "label": "", "metadata": {}, "score": "61.157745"}
{"text": "The combination of drugs in this study result in a more favorable toxicity profile than TFHX .Maintence gefitinib at 250 mg qd is tolerable .", "label": "", "metadata": {}, "score": "61.285015"}
{"text": "Chemotherapy regimens commonly used in our institution are described in the Table 1 .Cisplatin ( 100 mg / m 2 /3 weeks ) + 5-FU ( 1000 mg / m 2 /d , 4 days/3 weeks ) + Cetuximab ( 400 mg / m 2 then 250 mg / m 2 /week ) .", "label": "", "metadata": {}, "score": "61.429516"}
{"text": "Le Chevalier T , Brisgand D , Soria JC , et al : Long term analysis of survival in the European randomized trial comparing vinorelbine/ cisplatin to vindesine / cisplatin and vinorelbine alone in advanced non - small cell lung cancer .", "label": "", "metadata": {}, "score": "61.43824"}
{"text": "PF-00299804 is a second - generation quinazoline - based irreversible pan - HER inhibitor .In preclinical studies , PF-00299804 has much lower IC50 values than gefitinib in cell lines engineered to express EGFRvIII mutations ( 1.2 nM versus 2,700 nM ) and produces tumor growth inhibition in gefitinib - resistant xenografts .", "label": "", "metadata": {}, "score": "61.870747"}
{"text": "17 ] After the initial 68 PS 2 patients were enrolled , accrual was stopped due to a high incidence of adverse events , including five deaths .", "label": "", "metadata": {}, "score": "61.885105"}
{"text": "No preview \u00b7 Article \u00b7 Aug 2009 \u00b7 American journal of clinical oncology .Patients with initially palpable lymph nodes underwent neck dissection .Results .", "label": "", "metadata": {}, "score": "61.92519"}
{"text": "The dose limiting toxicities were abdominal pain within the radiation field , nausea and anorexia .The phase II Brown University study , utilizing paclitaxel 50 mg / m(2 ) per week for 6 weeks with 50.4 Gy radiation , demonstrated modest locoregional activity and acceptable toxicity .", "label": "", "metadata": {}, "score": "61.9756"}
{"text": "Patients received gemicitabine , 1 g / m(2)/week , for 7 of 8 weeks followed by 3 of every 4 weeks , and Herceptin , 4 mg / kg loading dose , followed by 2 mg / kg / week .", "label": "", "metadata": {}, "score": "62.005905"}
{"text": "Head Neck 2008 .[ Show abstract ] [ Hide abstract ] ABSTRACT : A phase I trial was conducted to determine the maximally tolerated dose ( MTD ) and dose - limiting toxicities ( DLTs ) of docetaxel , capecitabine , and carboplatin for first - line treatment of patients with metastatic esophageal and gastric cancers .", "label": "", "metadata": {}, "score": "62.022697"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu .", "label": "", "metadata": {}, "score": "62.04464"}
{"text": "Nonplatinum Agents and Combinations .ELVIS Trial -The Elderly Lung Cancer Vinorelbine Italian Study ( ELVIS ) conducted by Gridelli and colleagues was the first to assess the benefit of modern chemotherapy in elderly patients .", "label": "", "metadata": {}, "score": "62.095398"}
{"text": "To evaluate the impact on OS of factors known to be relevant in recurrent and/or metastatic HNSCC prognosis , potential prognostic factors were included in univariate and multivariate Cox proportional hazard regression models .", "label": "", "metadata": {}, "score": "62.263283"}
{"text": "The ability to alter treatment in an attempt to reduce toxicity is a luxury , provided by the fact that outcomes in these advanced patients are so good .", "label": "", "metadata": {}, "score": "62.40964"}
{"text": "Vansteenkiste JF , Vandebroek JE , Nackaerts KL , et al : Clinical - benefit response in advanced non - small - cell lung cancer : A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatinvindesine .", "label": "", "metadata": {}, "score": "62.427116"}
{"text": "Retrospective Data .ECOG Trial -A trial by ECOG published in 1986 was one of the first to illustrate inferior outcomes for PS 2 patients .", "label": "", "metadata": {}, "score": "62.706932"}
{"text": "Trastuzumab can be added at full dose to cisplatin , paclitaxel , and radiation .Future studies of trastuzumab in esophageal adenocarcinoma are indicated .[ Show abstract ] [ Hide abstract ] ABSTRACT : Purpose : To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu .", "label": "", "metadata": {}, "score": "62.99691"}
{"text": "The study was designed to compare the overall survival associated with each of the single agents vs the combination regimen .Toxicity was slightly higher in the combination arm , but treatment was well tolerated in general .", "label": "", "metadata": {}, "score": "63.087593"}
{"text": "10.1159/000074153 PubMed View Article .Clark JI , Hofmeister C , Choudhury A , Matz G , Collins S , Bastian R , Melian E , Emami B , Petruzzelli G : Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma .", "label": "", "metadata": {}, "score": "63.108074"}
{"text": "Results .Most patients received at least two treatment lines .The median overall survival was 9.8 months ( 95 % CI : 8.1 - 11.4 months ) and reached 13.1 months among the subgroup of 131 patients eligible for inclusion in a clinical trial .", "label": "", "metadata": {}, "score": "63.134285"}
{"text": "[ 8 ] A total of 155 elderly patients were enrolled , accounting for 27 % of the study population ( Table 2 ) .No significant differences in response or survival between the older and younger patients were reported .", "label": "", "metadata": {}, "score": "63.14776"}
{"text": "34 % had diarrhea ( no grade 4 ) .46 % had rash ( no grade 4 ) .14 % had grade 1 neuropathy ( no grade 2 - 5 ) .", "label": "", "metadata": {}, "score": "63.170547"}
{"text": "The substitution of paclitaxel with gefitinib in this trial yields the expected reductions in neuropathy and neutropenia .These can be the most dangerous toxicities in the short - term and most bothersome in the long - term .", "label": "", "metadata": {}, "score": "63.397484"}
{"text": "Written consent was obtained from each patient according to the institutional practice and french regulation .This study was approved by the ethics committee of the Centre L\u00e9on B\u00e9rard cancer center .", "label": "", "metadata": {}, "score": "63.405487"}
{"text": "Stage distribution was as follows : stage II , 3 patients ; stage III , 12 patients ; and stage IV , 8 patients .A total of 53 cycles ( range : 1 - 3 ) of HAI - oxaliplatin were delivered .", "label": "", "metadata": {}, "score": "63.69895"}
{"text": "Based on a better therapeutic index , a carboplatin - doublet would be preferable in elderly patients .On the other hand , elderly patients with severe comorbid conditions and a low functional capacity may be better served by single - agent therapy .", "label": "", "metadata": {}, "score": "63.96136"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01362374 RATIONALE : Drugs used in chemotherapy , such as capecitabine , work in different ways to stop the growth of tumor cells , either by killing the cells or by stopping them from dividing .", "label": "", "metadata": {}, "score": "64.0607"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Pancreatic adenocarcinomas are among the most resistant neoplasms to conventional chemotherapeutics .This has prompted intense investigations of novel non - cytotoxic agents based on new understandings of the molecular pathobiology of human malignancies .", "label": "", "metadata": {}, "score": "64.08728"}
{"text": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to ON 01910 .Na .Uncontrolled intercurrent illness including , but not limited to ongoing or active infection , bleeding , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , or psychiatric illness / social situations that would limit compliance with study requirements .", "label": "", "metadata": {}, "score": "64.213005"}
{"text": "Recurrent and/or metastatic head and neck squamous cell carcinoma Chemotherapy Survival analysis Treatment outcome Drug administration schedule .Background .Despite progress in the primary treatment of head and neck squamous cell carcinoma ( HNSCC ) by combining chemotherapy with surgery , radiation therapy and supportive care , recurrence rates range from 30 to 50 % .", "label": "", "metadata": {}, "score": "64.253815"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : A phase I study was performed to determine the maximally tolerated dose of carboplatin , ifosfamide , and docetaxel in advanced head and neck cancers .", "label": "", "metadata": {}, "score": "64.44662"}
{"text": "A greater than 50 % reduction in alphafetoprotein was seen in the 3 patients with partial responses and 3 patients with stable disease .HAI - oxaliplatin is a feasible , well tolerated , and demonstrated activity in this advanced HCC cohort .", "label": "", "metadata": {}, "score": "64.65534"}
{"text": "Vansteenkiste and colleagues from Belgium compared single - agent gemcitabine ( Gemzar ) to the combination of cisplatin and vindesine in a phase III trial with clinical benefit as the primary end point .", "label": "", "metadata": {}, "score": "64.93308"}
{"text": "No previous history of Lapatinib .Previous use of cetuximab in the curative - intention setting will not result in exclusion , as long as at least four weeks have elapsed since prior C225 exposure .", "label": "", "metadata": {}, "score": "64.99701"}
{"text": "[ 7 ] About 19 % of the patient population was age 70 or older .There were no significant differences in outcome , despite a trend toward a lower median survival in the elderly .", "label": "", "metadata": {}, "score": "65.151306"}
{"text": "Acute and late treatment toxicities [ Time Frame : All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment . ]", "label": "", "metadata": {}, "score": "65.39175"}
{"text": "In fact , the data discussed above should lead to the end of a discriminatory period in clinical research and to the elimination of the denomination \" special populations . \"", "label": "", "metadata": {}, "score": "65.94531"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Department of Medical Oncology , Centre L\u00e9on B\u00e9rard , University of Lyon .", "label": "", "metadata": {}, "score": "65.99646"}
{"text": "Results .Patient characteristics .Between March 2006 and August 2011 , a total of 198 patients with histologically confirmed HNSCC received chemotherapy at the Centre L\u00e9on B\u00e9rard ( Lyon , France ) for a recurrent and/or metastatic disease .", "label": "", "metadata": {}, "score": "66.25224"}
{"text": "Patients must neither be pregnant nor expect to become pregnant while on study .Patients must have the ability to understand and the willingness to sign a written informed consent document .", "label": "", "metadata": {}, "score": "66.65062"}
{"text": "Na will be determined by validated method .Patients will receive escalating doses of ON 01910 .Na ( 250 mg / m2 to 4450 mg / m2 ) intravenously by 24 hour continuous infusion once every week ( 3 weeks per cycle ) , until evidence of disease progression , intolerable adverse events , or withdrawal of patient consent .", "label": "", "metadata": {}, "score": "66.8295"}
{"text": "To assess the relationship between age and treatment , Ramsey and colleagues reviewed the Surveillance , Epidemiology , and End Results ( SEER )Medicare records from 1994 to 1999 .", "label": "", "metadata": {}, "score": "66.84825"}
{"text": "Adequate haematological , renal and hepatic functions as defined by : .Signed written consent .Suitable for follow - up for 4 years in the view of the investigator .", "label": "", "metadata": {}, "score": "66.93905"}
{"text": "After completion of study treatment , patients are followed every 3 months for up to 5 years .Metastatic disease or locally recurrent disease not felt amenable to curative therapy ( as determined by a physician ) .", "label": "", "metadata": {}, "score": "66.94811"}
{"text": "Tester WJ , Stphenson P , Langer CJ , et al : ECOG 1599 : Randomized phase II study of paclitxel / carboplatin vs cisplatin / gemcitabine in performance status ( PS ) 2 patients with treatment- na\u00efve advanced NSCLC ( abstract 7055 ) .", "label": "", "metadata": {}, "score": "67.0083"}
{"text": "Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics .HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization ( FISH ) .", "label": "", "metadata": {}, "score": "67.040306"}
{"text": "Restaging was done after two cycles , while dose level escalation was done in cohorts of three patients .No dose - limiting toxicities were observed .", "label": "", "metadata": {}, "score": "67.13214"}
{"text": "Primary Completion Date .October 2013 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : .Histologically confirmed squamous cell carcinoma of head and neck .", "label": "", "metadata": {}, "score": "67.16537"}
{"text": "10.1056/NEJMoa1000678 PubMed View Article .Grau JJ , Caballero M , Verger E , Monzo M , Blanch JL : Weekly paclitaxel for platin - resistant stage IV head and neck cancer patients .", "label": "", "metadata": {}, "score": "67.34013"}
{"text": "II .Time to disease progression and sites of progression .III .Response rate .IV .Toxicity of the combination in this population .", "label": "", "metadata": {}, "score": "67.349884"}
{"text": "Once all these patients have a 2 week post RT review there will be analysis .[ Designated as safety issue : Yes ] .Failure free survival ( FFS )", "label": "", "metadata": {}, "score": "67.37638"}
{"text": "Patients undergo a MRI of the liver with the new investigational agent and a CT with a routinely used contrast agent .Imaging tests are separated by 24 hours , and patients undergo blood work .", "label": "", "metadata": {}, "score": "67.38909"}
{"text": "Quality of life was evaluated prospectively .Patients treated with vinorelbine showed a significant survival advantage , most notably a 1-year survival rate of 32 % compared to 14 % for patients managed with supportive care alone ( Table 1 ) .", "label": "", "metadata": {}, "score": "67.40788"}
{"text": "Site of first failure [ Time Frame : All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment . ]", "label": "", "metadata": {}, "score": "67.42293"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01538563 Allocation : Non - Randomized Endpoint Classification : Safety Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "67.5621"}
{"text": "Detailed Description : .Secondary objectives are to estimate failure free survival ( FFS ) and overall survival , to evaluate the time to local and regional failure and to determine the site of first failure ( characterised as local , regional , distant or combinations ) .", "label": "", "metadata": {}, "score": "67.65744"}
{"text": "Patients received gemcitabine , 1 g / m2/week , for 7 of 8 weeks followed by 3 of every 4 weeks , and Herceptin , 4 mg / kg loading dose , followed by 2 mg / kg / week .", "label": "", "metadata": {}, "score": "67.79686"}
{"text": "Overall survival [ Time Frame : All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment . ]", "label": "", "metadata": {}, "score": "67.96543"}
{"text": "Investigational drugs are not permitted from 3 weeks ( 21 days ) or 5 half - lives , whichever is longer , prior to the first dose and up through 30 days after the last dose of investigational product .", "label": "", "metadata": {}, "score": "68.01549"}
{"text": "OUTLINE : .Patients receive oral lapatinib ditosylate once daily on days 1 - 21 and oral capecitabine twice daily on days 1 - 14 .", "label": "", "metadata": {}, "score": "68.09573"}
{"text": "14 ] Gemcitabine compared favorably to the combination of cisplatin and vindesine , with longer - lasting clinical benefit ( 16 vs 10 weeks ) and no major differences in survival ( 6.7 vs 5.5 months ) .", "label": "", "metadata": {}, "score": "68.116585"}
{"text": "Michigan Oncology Journal Fall 1999 .Of Interest - Clinical Trials and Clinical Services .Phase I trial using a dendritic cell vaccine for patients with refractory ovarian cancer who have received multiple prior chemotherapy regimens .", "label": "", "metadata": {}, "score": "68.15672"}
{"text": "T he management of advanced non - small - cell lung cancer ( NSCLC ) has evolved considerably in the past decade .The positive impact of chemotherapy on the survival and quality of life of advanced NSCLC patients is now accepted by most patients and physicians .", "label": "", "metadata": {}, "score": "68.16763"}
{"text": "Must have normal organ and marrow function .Laboratory tests should be completed within 14 days prior to registration .Left ventricular ejection fraction ( LVEF ) can be determined by either echocardiography or nuclear scintigraphy and should be obtained within 21 days of enrollment .", "label": "", "metadata": {}, "score": "68.27629"}
{"text": "Prospective Data .CALGB Trial -The CALGB 9730 trial discussed above enrolled 99 patients with PS 2 , the largest number ever accrued to a cooperative group phase III trial in the United States .", "label": "", "metadata": {}, "score": "68.3119"}
{"text": "Experimental : PF-00299804 .Intervention : Drug : PF-00299804 .Not Provided .Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .", "label": "", "metadata": {}, "score": "68.33906"}
{"text": "The CALGB trial , while provocative , should not be considered definitive and further studies are needed .Another important question in PS 2 patients is whether the new molecularly targeted agents have a role in the management of their disease .", "label": "", "metadata": {}, "score": "68.50284"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "68.710815"}
{"text": "The difference was statistically significant and , indeed , of greater magnitude than observed between the two arms in PS 0/1 patients .Analysis of quality - of - life parameters showed no detriment in PS 2 patients treated with the combination .", "label": "", "metadata": {}, "score": "68.743"}
{"text": "Refusal by male or female patients , to use appropriate contraception during the study and for 3 months afterwards .Any condition or circumstance which might prevent the patient being able to give valid informed consent , or from completing participation in the study .", "label": "", "metadata": {}, "score": "68.78349"}
{"text": "Distant metastases , i.e. , any metastatic disease below the clavicles .Patients with lesions 5 - 10 mm can be included if a FDG - PET scan is negative and the investigator considers on clinical grounds that metastasis is unlikely .", "label": "", "metadata": {}, "score": "68.82825"}
{"text": "However because all consecutive patients treated in our institution have been included in this series , it might be a relevant estimation of \" real life \" patient outcomes .", "label": "", "metadata": {}, "score": "68.93235"}
{"text": "Grade 3/4 neutropenia : 33 % .Neuropathy ( any grade ) : up to 33 % .Grade 3/4 mucositis : 76 % .Paclitaxel dose reduction : 40 % .", "label": "", "metadata": {}, "score": "69.06761"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : To perform a phase II trial evaluating dose dense induction chemotherapy for locally advanced head and neck cancer .", "label": "", "metadata": {}, "score": "69.1281"}
{"text": "ON 01910 .Na Concentrate .ON 01910 .Na . rigosertib .Detailed Description : .This is an open - label , dose - escalating Phase I study of ON 01910 .", "label": "", "metadata": {}, "score": "69.31733"}
{"text": "Total bilirubin within 1.5 times institutional upper normal limit .Patients with primary liver disease with these parameters will be ineligible . )Women of child - bearing potential and men must agree to use adequate contraception prior to study entry .", "label": "", "metadata": {}, "score": "69.51286"}
{"text": "[ 18 ] In fact , only two of the five deaths were directly attributed to toxicity , while the others were thought to be secondary to disease .", "label": "", "metadata": {}, "score": "69.94551"}
{"text": "Therefore , we retrospectively analyzed the outcomes of patients treated in a single institution , where the administration of successive lines of chemotherapies has been the standard clinical approach .", "label": "", "metadata": {}, "score": "70.28833"}
{"text": "Improvements in locoregional control are needed despite the use of 3 agents to enhance the effects of radiation .No preview \u00b7 Article \u00b7 Dec 2012 \u00b7 American journal of clinical oncology .", "label": "", "metadata": {}, "score": "70.6926"}
{"text": "In this article , we will review these data and discuss the potential implications for clinical practice .Elderly Patients Approximately two - thirds of newly diagnosed patients with NSCLC are 65 years of age or older , and 40 % are older than 70 years .", "label": "", "metadata": {}, "score": "70.87804"}
{"text": "Sweeney C , Zhu J , Sandler A , et al : Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 : A phase III trial in metastatic non - small cell lung carcinoma .", "label": "", "metadata": {}, "score": "71.053314"}
{"text": "A total of 92 patients ( 19 % ) had a PS of 2 .The median survival for PS 0 and PS 1 patients was 36 and 26 weeks , respectively , whereas for PS 2 patients , it was 10 weeks .", "label": "", "metadata": {}, "score": "71.44101"}
{"text": "In 1992 , in a trial comparing cisplatin and 5FU as single agents and in combination , the response rate to the combination was higher but survival did not improve .", "label": "", "metadata": {}, "score": "71.89586"}
{"text": "Nature adverse events and laboratory abnormalities graded per NCI CTCAE v4.03 [ Time Frame : Until 30 days after last dose of study treatment or until initiation of another anti - cancer therapy , whichever occurs first ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "72.33909"}
{"text": "Concurrent radiation therapy and surgery for SCCHN is prohibited during therapy .Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "72.932755"}
{"text": "Giving capecitabine together with lapatinib ditosylate may kill more tumor cells .PURPOSE : This phase II trial is studying how well giving capecitabine and lapatinib ditosylate together works in treating patients with squamous cell cancer of the head and neck .", "label": "", "metadata": {}, "score": "73.134735"}
{"text": "CNRS UMR 5558 , Laboratoire de Biom\u00e9trie et Biologie Evolutive , Equipe Biostatistique - Sant\u00e9 .Department of Biostatistics , University of Lyon , Centre L\u00e9on B\u00e9rard .", "label": "", "metadata": {}, "score": "73.61145"}
{"text": "After a median follow - up of 33.4 months , a total of 156 patients ( 79 % ) had died .The median OS was 9.8 months ( 95 % CI : 8.1 - 11.4 months )", "label": "", "metadata": {}, "score": "74.18659"}
{"text": "After Failure of Platinum - containing Therapy .Brief Summary .Epidermal growth factor receptor ( EGFR ) is often over - expressed , and have been related to poor prognosis in patients with HNSCC .", "label": "", "metadata": {}, "score": "74.30701"}
{"text": "PubMed View Article .Anticancer Drugs 2012 , 23 ( 9 ) : 996 - 1001 .PubMed .Anticancer Drugs 2010 , 21 ( 5 ) : 553 - 558 .", "label": "", "metadata": {}, "score": "74.497894"}
{"text": "For these reasons , carboplatin and weekly paclitaxel was the standard carboplatin - based regimen in this series .For patients ineligible or resistant to a platinum therapy , less toxic first line regimens have been offered to patients .", "label": "", "metadata": {}, "score": "74.84192"}
{"text": "Dose levels were escalated independently for patients with and without previous chemotherapy exposure and advanced malignancies .Both agents were administered weekly for 6 weeks followed by a 2-week break per cycle .", "label": "", "metadata": {}, "score": "75.227646"}
{"text": "MILES Trial -The Multicentre Italian Lung Cancer in the Elderly Study ( MILES ) was the largest trial ever conducted in elderly patients with advanced NSCLC .", "label": "", "metadata": {}, "score": "76.00987"}
{"text": "Confirmed partial responses were observed in 2 of 32 patients ( 6 % ) .The median survival for all 34 patients was 7 months , and the 1-year survival was 19 % .", "label": "", "metadata": {}, "score": "76.47367"}
{"text": "Confirmed partial responses were observed in 2 of 32 patients ( 6 % ) .The median survival for all 34 patients was 7 months , and the 1-year survival was 19 % .", "label": "", "metadata": {}, "score": "76.47367"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00704639", "label": "", "metadata": {}, "score": "77.53125"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01044433 .Paranasal Sinus Neoplasms Carcinoma Carcinoma , Squamous Cell Carcinoma , Verrucous Head and Neck Neoplasms Laryngeal Diseases Laryngeal Neoplasms Neoplasms , Unknown Primary Oropharyngeal Neoplasms Salivary Gland Neoplasms Mouth Diseases Mouth Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type .", "label": "", "metadata": {}, "score": "77.74809"}
{"text": "Na in plasma versus time [ Time Frame : Up to 48 hours after infusion of study drug during Week 1 in Cycles 1 and 2 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "77.90423"}
{"text": "The addition of gemcitabine to paclitaxel and radiation has also demonstrated promising preliminary activity and a phase II study by the RTOG is being initiated .", "label": "", "metadata": {}, "score": "78.16101"}
{"text": "JP and JF participated in the design of the study .JP , VP and SC performed the statistical analysis .JP and JF participated in the coordination and helped to draft the manuscript .", "label": "", "metadata": {}, "score": "79.867004"}
{"text": "Head Neck Cancer Squamous Cell Recurrent .Intervention ICMJE .Drug : PF-00299804 .45 mg P.O. Daily ( 28-day treatment as one treatment cycle ) .", "label": "", "metadata": {}, "score": "81.068344"}
{"text": "Eur J Cancer 2004 , 40 ( 14 ) : 2071 - 2076 .10.1016/j.ejca.2004.05.019 PubMed View Article .Br J Cancer 2010 , 102 ( 12 ) : 1687 - 1691 .", "label": "", "metadata": {}, "score": "83.7906"}
{"text": "CO;2 - 3 PubMed View Article .Oral Oncol 2013 , 49 ( 2 ) : 182 - 185 .10.1016/j.oraloncology.2012.09.003 PubMed View Article .", "label": "", "metadata": {}, "score": "84.2216"}
{"text": "Presenter : E.E.W. Cohen Presenter 's Affiliation : University of Chicago Type of Session : Scientific .Background .This regimen has yielded 3-year overall survival ( OS ) of 70 % and 3-year progression - free survival ( PFS ) of 80 - 90 % .", "label": "", "metadata": {}, "score": "84.522995"}
{"text": "No preview \u00b7 Article \u00b7 Sep 2009 \u00b7 American journal of clinical oncology .[ Show abstract ] [ Hide abstract ] ABSTRACT : We performed a phase I study to evaluate the feasibility and determine the maximally tolerated dose of hepatic arterial infusion ( HAI ) of oxaliplatin in advanced hepatocellular carcinoma ( HCC ) .", "label": "", "metadata": {}, "score": "86.38626"}
{"text": "October 2013 ( final data collection date for primary outcome measure ) .Current Primary Outcome Measures ICMJE ( submitted : October 9 , 2011 ) .", "label": "", "metadata": {}, "score": "86.48877"}
{"text": "The Elderly Lung Cancer Vinorelbine Italian Study Group : Effect of vinorelbine on quality of life and survival of elderly patients with advanced non - small cell lung cancer .", "label": "", "metadata": {}, "score": "86.72106"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "87.35239"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "87.35239"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "87.35239"}
{"text": "N Engl J Med 2008 , 359 ( 11 ) : 1116 - 1127 .10.1056/NEJMoa0802656 PubMed View Article .J Clin Oncol 2007 , 25 ( 16 ) : 2171 - 2177 .", "label": "", "metadata": {}, "score": "87.70134"}
{"text": "J Clin Oncol 1992 , 10 ( 8) : 1245 - 1251 .PubMed .J Clin Oncol 2005 , 23 ( 15 ) : 3562 - 3567 .", "label": "", "metadata": {}, "score": "88.67186"}
{"text": "In an effort to reduce the toxicity from therapy , this study was designed to explore the replacement of paclitaxel in the standard regimen at the University of Chicago with gefitinib , a small molecule , tyrosine kinase inhibitor of EGFR .", "label": "", "metadata": {}, "score": "89.01963"}
{"text": "CALGB Trial -The Cancer and Leukemia Group B ( CALGB ) performed a randomized trial of carboplatin/ paclitaxel vs paclitaxel alone ( CALGB 9730 ) .", "label": "", "metadata": {}, "score": "91.00023"}
{"text": "10.1097/CAD.0b013e328358d226 PubMed View Article .J Clin Oncol .ASCO meeting : 2 - 5 june 2012 , Chicago 2012 .30(15s ) , ( suppl ; abstr 5505 ) .", "label": "", "metadata": {}, "score": "92.260284"}
{"text": "Cochrane Database Syst Rev 2009 , 2 : CD003372 .PubMed .J Clin Oncol 2003 , 21 ( 4 ) : 588 - 592 .", "label": "", "metadata": {}, "score": "93.88834"}
{"text": "Department of Otorhinolaryngology , Centre Hospitalier Lyon Sud , University of Lyon .Department of Otorhinolaryngology , H\u00f4pital E Herriot , University of Lyon .Department of Otorhinolaryngology , Centre L\u00e9on B\u00e9rard , University of Lyon .", "label": "", "metadata": {}, "score": "93.95327"}
{"text": "Disclosures .Dr. Lilenbaum receives research grant support , is a consultant and member of the speaker 's bureau for Bristol - Myers Squibb , Lilly , Aventis , and GlaxoSmithKline .", "label": "", "metadata": {}, "score": "95.97119"}
{"text": "Dr Julien P\u00e9ron is the recipient of a grant from the Nuovo - Soldati research foundation .Competing interest .The authors declare that they have no competing interest .", "label": "", "metadata": {}, "score": "99.53166"}
{"text": "Lancet Oncol 2011 , 12 ( 11 ) : 1032 - 1044 .10.1016/S1470 - 2045(11)70199 - 1 PubMed View Article .Ann Oncol 2010 , 21 : 1967 - 1973 .", "label": "", "metadata": {}, "score": "110.20203"}
{"text": "10.1002/cncr.21579 PubMed View Article .Pre - publication history .Copyright .\u00a9 P\u00e9ron et al . ; licensee BioMed Central Ltd. 2014 .", "label": "", "metadata": {}, "score": "115.17104"}
